Reports Q2 revenue $0 vs. $643,000 last year. “The team has made outstanding progress in a short amount of time toward initiating the Phase 2 LOTUS Trial, as highlighted by the activation of the IND in July,” said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. “Furthermore, the Company is immediately benefiting from the addition of Mittie and Paul to the leadership team as CMO and CLO, respectively. Their deep expertise and leadership experience will guide us as we focus on initiating the LOTUS Trial, as well as the evaluation and announcement of a second indication, both of which we believe are on track for the second half of the year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Avalo Therapeutics Welcomes New CMO with Competitive Package
- Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
- Avalo Therapeutics appoints Doyle as Chief Medical Officer
- Avalo Therapeutics announces active IND for AVTX-009